



IFW 1614

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. RLL-293US	
In Re Application Of: Mehta et al.						
						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/552,456	08/14/2006	Unknown	26815	1614	2308	
Title: SUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS						
<p>Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p> <p><b>37 CFR 1.97(b)</b></p> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p><b>37 CFR 1.97(c)</b></p> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p><b>OR</b></p> <p><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p>						

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
RLL-293US

In Re Application of: Mehta et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/552,456	08/14/2006	Unknown	26815	1614	2308

Title: SUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

September 20, 2006

(Date)

Signature of Person Mailing Correspondence

Christine Kenedy-Renner

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

William D Hane  
Signature

Dated: September 20, 2006

CC:

# INFORMATION DISCLOSURE CITATION


Docket No.: RLL-293US

Serial No.: 10/552,456

Applicants: MEHTA *et al.*

Filed: 10/7/2005

Group:



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	3,176,019	3/30/1965	Campbell <i>et al.</i>	260	293.4	
	A2	5,281,601	1/25/1994	Cross <i>et al.</i>	514	320	
	A3	5,397,800	3/14/1995	Alker <i>et al.</i>	514	413	
	A4	5,559,269	9/24/1996	Johansson <i>et al.</i>	564	443	
	A5	5,948,792	9/7/1999	Tsuchiya <i>et al.</i>	514	317	
	A6	6,130,232	10/10/2000	Mase <i>et al.</i>	514	318	
	A7	6,174,900	1/16/2001	Okada <i>et al.</i>	514	317	


## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO	
	B1	EP 0 325 571	7/26/1989	EPO	C07C	215/54		
	B2	EP 0 388 054	9/19/1990	EPO	C07D	207/08		
	B3	EP 0 801 067	10/15/1997	EPO	C07D	453/02		
	B4	EP 0 823 423	2/11/1998	EPO	C07D	211/46		
	B5	GB 940,540	10/30/1963	UK	C07C			
	B6	JP 135958/1994	5/17/1994	Japan	C07D	333/16		
	B7	JP 92921/1994	4/5/1994	Japan	C07C	237/20		
	B8	WO 91/09013	6/27/1991	PCT	C07D	207/08		
	B9	WO 93/16018	8/19/1993	PCT	C05F	17/02		
	B10	WO 93/16048	8/19/1993	PCT	C07D	211/26		
	B11	WO 96/33973	10/31/1996	PCT	C07D	211/46		
	B12	WO 97/45414	12/4/1997	PCT	C07D	211/58		
	B13	WO 98/00016	1/8/1998	PCT	A01N	43/38		
	B14	WO 98/00109	1/8/1998	PCT	A61K	9/08		

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<b>INFORMATION DISCLOSURE CITATION</b> 	Docket No.: RLL-293US	Serial No.: 10/552,456
	Applicants: MEHTA <i>et al.</i>	
	Filed: 10/7/2005	Group:

B15	WO 98/00132	1/8/1998	PCT	A61K	31/40		
B16	WO 98/00133	1/8/1998	PCT	A61K	31/40		
B17	WO 98/05641	2/12/1998	PCT	C07D	211/46		
B18	WO 98/29402	7/9/1998	PCT	C07D	311/20		

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Kubo et al., "Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor", <i>Nature</i> , <u>323</u> (2):411-416 (1986)
C2	Bonner et al., "Identification of a Family of Muscarinic Acetylcholine Receptor Genes", <i>Science</i> , <u>237</u> :527-531 (1987)
C3	Eglen et al., "Muscarinic receptor ligands and their theraputic potential", <i>Current Opinion in Chemical Biology</i> , <u>3</u> :426-432 (1999)
C4	Eglen et al., "Theraputic opportunities from muscarinic receptor research", <i>Trends in Pharmacological Sciences</i> , <u>22</u> (8):409-414 (2001)
C5	Felder et al., "Theraputic Opportunities for Muscarinic Receptors in the Central Nervous System", <i>Journal of Medicinal Chemistry</i> , <u>43</u> (23):4333-4353 (2000)
C6	Broadley and Kelly, "Muscarinic Receptor Agonists and Antagonists", <i>Molecules</i> , <u>6</u> :142-193 (2001)
C7	Birdsall et al., "Muscarinic receptors: it's a knockout", <i>Trends in Pharmacological Sciences</i> , <u>22</u> (5):215-219 (2001)
C8	de Groat and Yoshimura, "Pharmacology of the Lower Urinary Tract", <i>Annual Review of Pharmacology and Toxicology</i> , <u>41</u> :691-721 (2001)
C9	Steers, "The future direction of neuro-urology drug research", <i>Current Opinion in CPNS Investigational Drugs</i> , <u>2</u> (3):268-282
C10	Chapple, "Muscarinic receptor antagonists in the treatment of overactive bladder", <i>Urology</i> , <u>55</u> (Suppl. 5A):33-46 (2000)
C11	Steers, Barrot, Wein, "Voiding dysfunction: diagnosis classification and management", In: <i>Adult and Pediatric Urology</i> , ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996)
C12	Sagara et al., "Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M3 Antagonist Discriminating against the Other Receptor Subtypes", <i>Journal of Medicinal Chemistry</i> , <u>45</u> :984-987 (2002)
C13	Braish et al., "Construction of the (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-Amino-3-azabicyclo[3.1.0]hexane Ring System", <i>Synlett</i> , 1100-1102 (1996)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE CITATION</b> 	Docket No.: RLL-293US	Serial No.: 10/552,456
	Applicants: MEHTA <i>et al.</i>	
	Filed: 10/7/2005	Group:

		Moriya et al., "Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland", <i>Life Sciences</i> , <u>64</u> (25):2351-2358 (1999)
	C15	Cheng and Prusoff, "Relationship between the inhibition constant ( <i>K</i> <sub>1</sub> ) and the concentration of inhibitor which causes 50 per cent inhibition ( <i>I</i> <sub>50</sub> ) of an enzymatic reaction", <i>Biochemical Pharmacology</i> , <u>22</u> :3099-3108 (1973)
	C16	Andersson et al, "Asymmetric Total Synthesis of (+)-Tolterodine, a New Muscarinic Receptor Antagonist, via Copper-Assisted Asymmetric Conjugate Addition of Aryl Gridngard Reagents to 3-Phenyl-prop-2-enoyl-oxazolidinones", <i>Journal of Organic Chemistry</i> , <u>63</u> (22): 8067-8070 (1998)

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	